Cariprazine (Vraylar)
Major Depressive Disorder (adjunctive)
Key Facts
Indication
Major Depressive Disorder (adjunctive)
Phase
Phase III / Filed
Status
Active
Company
About Richter Gedeon
Richter Gedeon's mission is to improve patient lives through the research, development, and global commercialization of innovative pharmaceuticals. The company has achieved a dominant position in its core Central and Eastern European markets while expanding its international footprint, supported by a robust pipeline of 34 candidates. Its strategy is built on deep therapeutic expertise in women's health and CNS, vertical integration from API to finished product, and a disciplined approach to both organic R&D and strategic partnerships to fuel sustainable growth.
View full company profileTherapeutic Areas
Other Major Depressive Disorder (adjunctive) Drugs
| Drug | Company | Phase |
|---|---|---|
| LATUDA® (lurasidone HCl) | Sumitomo Pharma | Launched / Phase 3 |